Use of adjuvanted trivalent influenza vaccine in older-age adults: a systematic review of economic evidence

References

• World Health Organization (WHO). Vaccines against influenza WHO position paper – november 2012. Wkly Epidemiol Rec. 2012;87:461–76.
   PubMedGoogle Scholar
• Cassini A, Colzani E, Pini A, Mangen MJ, Plass D, McDonald SA, Maringhini G, van Lier A, Haagsma JA, Havelaar AH, et al. Impact of infectious diseases on population health using incidence-based disability-adjusted life years (DALYs): results from the burden of communicable diseases in Europe study, European union and European economic area countries, 2009 to 2013. Euro Surveill. 2018 Apr;23(16). doi:10.2807/1560-7917.ES.2018.23.16.17-00454. PubMed PMID: 29692315; PubMed Central PMCID: PMC5915974.
   Google Scholar
• Panatto D, Signori A, Lai PL, Gasparini R, Amicizia D. Heterogeneous estimates of influenza virus types A and B in the elderly: results of a meta-regression analysis. Influenza Other Respir Viruses. 2018 Mar 2;12:533–43. doi:10.1111/irv.12550. Epub ahead of print.
   PubMed Web of Science ®Google Scholar
• Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, Fukuda K. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003 Jan 8;289(2):179–86.
   Google Scholar
• de Lusignan S, Correa A, Ellis J, Pebody R. Influenza vaccination: in the UK and across Europe. Br J Gen Pract. 2016 Sep;66(650):452–53. doi:10.3399/bjgp16X686677.
   Google Scholar
• Hannoun C The evolving history of influenza viruses and influenza vaccines. Expert Rev Vaccines. 2013 Sep;12(9):1085–94. doi:10.1586/14760584.2013.824709. Epub 2013 Sep 12.
   Google Scholar
• Treanor JJ. Clinical practice. Influenza vaccination. N Engl J Med. 2016;375:1261–68. doi:10.1056/NEJMcp1512870. PMID:27682035.
   Google Scholar
• Demicheli V, Jefferson T, Di Pietrantonj C, Ferroni E, Thorning S, Thomas RE, Rivetti A. Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev. 2018 Feb 1;2:CD004876. doi:10.1002/14651858.CD004876.pub4. Review. PubMed PMID: 29388197.
   PubMed Web of Science ®Google Scholar
• Beyer WE, McElhaney J, Smith DJ, Monto AS, Nguyen-Van-Tam JS, Osterhaus AD. Cochrane re-arranged: support for policies to vaccinate elderly people against influenza. Vaccine. 2013;31(50):6030–33. doi:10.1016/j.vaccine.2013.09.063.
   PubMed Web of Science ®Google Scholar
• Bragazzi NL, Orsi A, Ansaldi F, Gasparini R, Icardi G. Fluzone® intra-dermal (Intanza®/Istivac® Intra-dermal): an updated overview. Hum Vaccin Immunother. 2016 Oct 2;12(10):2616–27. doi:10.1080/21645515.2016.1187343. Epub 2016 May 31.
   PubMed Web of Science ®Google Scholar
• Robertson CA, DiazGranados CA, Decker MD, Chit A, Mercer M, Greenberg DP. Fluzone® high-dose influenza vaccine. Expert Rev Vaccines. 2016 Dec;15(12):1495–505. doi:10.1080/14760584.2016.1254044. Epub 2016 Nov 14.
   PubMed Web of Science ®Google Scholar
• O’Hagan DT, Rappuoli R, De Gregorio E, Tsai T, Del Giudice G. MF59 adjuvant: the best insurance against influenza strain diversity. Expert Rev Vaccines. 2011 Apr;10(4):447–62. doi:10.1586/erv.11.23.
   PubMed Web of Science ®Google Scholar
• Shields GE, Elvidge J, Davies LM. A systematic review of economic evaluations of seasonal influenza vaccination for the elderly population in the European Union. BMJ Open. 2017 Jun 10;7(6):e014847. doi:10.1136/bmjopen-2016-014847.
   PubMed Web of Science ®Google Scholar
• Ting EEK, Sander B, Ungar WJ. Systematic review of the cost-effectiveness of influenza immunization programs. Vaccine. 2017 Apr 4;35(15):1828–43. doi:10.1016/j.vaccine.2017.02.044. Epub 2017 Mar 9. Review. PubMed PMID: 28284681.
   PubMed Web of Science ®Google Scholar
• D’Angiolella LS, Lafranconi A, Cortesi PA, Rota S, Cesana G, Mantovani LG Costs and effectiveness of influenza vaccination: a systematic review. Ann Ist Super Sanita. 2018 Jan-Mar;54(1):49–57. doi:10.4415/ANN_18_01_10. PubMed PMID: 29616674.
   PubMed Web of Science ®Google Scholar
• European Centre for Disease Prevention and Control (ECDC). Seasonal influenza vaccination and antiviral use in Europe – overview of vaccination recommendations and coverage rates in the EU Member States for the 2013–14 and 2014–15 influenza seasons. Stockholm: ECDC; 2016. https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/Seasonal-influenza-vaccination-antiviral-use-europe.pdf.
   Google Scholar
• Donaldson C, Mugford M, Vale L, eds. Evidence-based Health Economic: from effectiveness to efficiency in systematic review. London, UK: BMJ Books; 2002.
   Google Scholar
• de Boer PT, van Maanen BM, Damm O, Ultsch B, Dolk FCK, Crépey P, Pitman R, Wilschut JC, Postma MJ A systematic review of the health economic consequences of quadrivalent influenza vaccination. Expert Rev Pharmacoecon Outcomes Res. 2017 Jun;17(3):249–65. doi:10.1080/14737167.2017.1343145. Epub 2017 Jun 28.
   PubMed Web of Science ®Google Scholar
• Public Health England (PHE). Guidance. Summary of data to support the choice of influenza vaccination for adults in primary care. https://www.gov.uk/government/publications/flu-vaccination-supporting-data-for-adult-vaccines/summary-of-data-to-support-the-choice-of-influenza-vaccination-for-adults-in-primary-care.
   Google Scholar
• Italian Ministry of Health. Prevention and control of influenza: recommendations for the season 2018/19. http://www.trovanorme.salute.gov.it/norme/renderNormsanPdf?anno=2018&codLeg=64381&parte=1%20&serie=null.
   Google Scholar
• Fluad®. Prescribing information. http://www.fluad.com/Common/docs/FLUAD_Package_Insert.pdf
   Google Scholar
• Gomersall JS, Jadotte YT, Xue Y, Lockwood S, Riddle D, Preda A. Conducting systematic reviews of economic evaluations. Int J Evid Based Healthc. 2015 Sep;13(3):170–78. doi:10.1097/XEB.0000000000000063.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. doi:10.1371/journal.pmed.1000097.
   PubMed Web of Science ®Google Scholar
• An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI). Literature review on pediatric Fluad® influenza vaccine use in children 6-72 months of age. http://www.phac-aspc.gc.ca/naci-ccni/assets/pdf/pediatric-pediatrique-fluad-eng.pdf
   Google Scholar
• Domnich A, Arata L, Amicizia D, Puig-Barberà J, Gasparini R, Panatto D. Effectiveness of MF59-adjuvanted seasonal influenza vaccine in the elderly: A systematic review and meta-analysis. Vaccine. 2017 Jan 23;35(4):513–20. doi:10.1016/j.vaccine.2016.12.011. Epub 2016 Dec 23. Review. PubMed PMID: 28024956.
   PubMed Web of Science ®Google Scholar
• Schmucker CM, Blümle A, Schell LK, Schwarzer G, Oeller P, Cabrera L, von Elm E, Briel M, Meerpohl JJ. OPEN consortium. Systematic review finds that study data not published in full text articles have unclear impact on meta-analyses results in medical research. PLoS One. 2017 Apr 25;12(4):e0176210. doi:10.1371/journal.pone.0176210. eCollection 2017.
   PubMed Web of Science ®Google Scholar
• Burton HE, Mitchell SA, Watt M. A systematic literature review of economic evaluations of antibiotic treatments for Clostridium difficile infection. Pharmacoeconomics. 2017 Nov;35(11):1123–40. doi:10.1007/s40273-017-0540-2.
   PubMed Web of Science ®Google Scholar
• Organization for Economic Co-operation and Development (OECD). Consumer price indices. https://stats.oecd.org/Index.aspx?DataSetCode=PRICES_CPI&_ga=2.40857698.1932218757.1546681581-1435710676.1546681579#
   Google Scholar
• Organization for Economic Co-operation and Development (OECD). Exchange rates. https://data.oecd.org/conversion/exchange-rates.htm#indicator-chart
   Google Scholar
• Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, Augustovski F, Briggs AH, Mauskopf J, Loder E, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Value Health. 2013;16(2):e1–5. doi:10.1016/j.jval.2013.02.010.
   PubMed Web of Science ®Google Scholar
• Piercy J, Ryan J, Megas F. Economic evaluation of MF59 adjuvanted vaccine against influenza in the high-risk elderly population in France. J Med Econ. 2004;7:1–18. doi:10.3111/200407001018.
   Google Scholar
• Baio G, Pammolli F, Baldo V, Trivello R. Object-oriented influence diagram for cost-effectiveness analysis of influenza vaccination in the Italian elderly population. Expert Rev Pharmacoecon Outcomes Res. 2006;6(3):293–301. doi:10.1586/14737167.6.3.293.
   PubMedGoogle Scholar
• Iannazzo S, Sacchi V. Valutazione farmacoeconomica dei programmi di vaccinazione influenzale nella popolazione anziana italiana. Farmacoeconomia E Percorsi Terapeutici. 2009;10(2):59–72. doi:10.7175/fe.v10i2.164.
   Google Scholar
• Lee BY, Ercius AK, Smith KJ. A predictive model of the economic effects of an influenza vaccine adjuvant for the older adult (age 65 and over) population. Vaccine. 2009;27(16):2251–57. doi:10.1016/j.vaccine.2009.02.024.
   PubMed Web of Science ®Google Scholar
• Fisman DN, Tuite AR. Estimation of the health impact and cost-effectiveness of influenza vaccination with enhanced effectiveness in Canada. PLoS One. 2011;6(11):e27420. doi:10.1371/journal.pone.0027420.
   PubMed Web of Science ®Google Scholar
• Iannazzo S. Pharmacoeconomic evaluation of the MF59-adjuvanted influenza vaccine in the elderly population in Italy. J Prev Med Hyg. 2011;52:1–8.
   PubMedGoogle Scholar
• Mullikin M, Tan L, Jansen JP, Van Ranst M, Farkas N, Petri E. A Novel dynamic model for health economic analysis of influenza vaccination in the elderly. Infect Dis Ther. 2015;4(4):459–87. doi:10.1007/s40121-015-0076-8. Erratum in: Infect Dis Ther. 2015;4(4):489–90.
   PubMed Web of Science ®Google Scholar
• Ruiz-Aragón J, Grande Tejadab AM, Márquez-Peláezc S, García-Cenozd M. Estimación del impacto de la vacunación antigripal con adyuvante MF59 en población mayor de 64 años para el Sistema Nacional de Salud: efectos y costes. Vacunas. 2015;16:6–11. doi:10.1016/j.vacun.2015.02.002.
   Google Scholar
• Garlapati S. Decision analytic modeling for cost-effectiveness evaluation of adjuvanted and non-adjuvanted flu vaccines in the elderly 65+. J Vaccines Vaccn. 2016;2:00028.
   Google Scholar
• Raviotta JM, Smith KJ, DePasse J, Brown ST, Shim E, Nowalk MP, Zimmerman RK. Cost-effectiveness and public health effect of influenza vaccine strategies for U.S. elderly adults. J Am Geriatr Soc. 2016;64(10):2126–31. doi:10.1111/jgs.2016.64.issue-10.
   PubMed Web of Science ®Google Scholar
• Barbieri M, Capri S, Waure C, Boccalini S, Panatto D. Age- and risk-related appropriateness of the use of available influenza vaccines in the Italian elderly population is advantageous: results from a budget impact analysis. J Prev Med Hyg. 2017 Dec 30;58(4):E279–E287. doi:10.15167/2421-4248/jpmh2017.58.4.867. eCollection 2017 Dec. PubMed PMID: 29707658; PubMed Central PMCID: PMC5912787.
   PubMedGoogle Scholar
• Pérez-Rubio A, Eiros JM. Economic and Health impact of influenza vaccination with adjuvant MF59 in population over 64 years in Spain. Rev Esp Quimioter. 2018 Feb;31(1):43–52. Epub 2017 Jan 18. Spanish. PubMed PMID: 29355006.
   PubMed Web of Science ®Google Scholar
• Capri S, Barbieri M, de Waure C, Boccalini S, Panatto D. Cost-effectiveness analysis of different seasonal influenza vaccines in the elderly Italian population. Hum Vaccin Immunother. 2018 Jun 3;14(6):1331–41. doi:10.1080/21645515.2018.1438792. Epub 2018 Feb 26. PubMed PMID: 29425079; PubMed Central PMCID: PMC6037461.
   PubMed Web of Science ®Google Scholar
• Petri E. Cost-effectiveness analyses of various seasonal influenza vaccines available for elderly in Germany. Eur J Public Health. 2015;25(Suppl 3):436. doi:10.1093/eurpub/ckv176.167.
   Google Scholar
• Petri E A comparison of cost-effectiveness of seasonal influenza vaccines in Spain. Presented at IVW Conference; 2015 Oct 6–9; Albufeira (Portugal).
   Google Scholar
• Petri E Health economics for seasonal influenza vaccination of older adults in Italy. Presented at Options IX conference underscores our commitment to the prevention and control of seasonal influenza, Chigago, US.
   Google Scholar
• Nguyen VH, Kelly C, Mansi JA UK health economic model demonstrates use of adjuvanted trivalent seasonal influenza vaccine in older adults to be highly cost-effective. Presented at ESWI, Riga, Latvia.
   Google Scholar
• Fisman D, Tuite A Estimating the relative cost-effectiveness of competing seasonal influenza vaccination programs in Canada: a multi-strain dynamic modeling approach. Presented at: ECCMID, Madrid, Spain.
   Google Scholar
• Smith PC Measuring value for money in healthcare: concepts and tools. https://www.who.int/pmnch/topics/economics/20091027_smith/en/
   Google Scholar
• The Australian Immunisation Handbook. 10th ed. [ accessed 2018 Feb]. http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/90ADD02CDCB5D49DCA257D4D0022D886/$File/4-7-Influenza-2018-02-19.pdf.
   Google Scholar
• Bonanni P, Boccalini S, Zanobini P, Dakka N, Lorini C, Santomauro F, Bechini A. The appropriateness of the use of influenza vaccines: recommendations from the latest seasons in Italy. Hum Vaccin Immunother. 2018 Mar 4;14(3):699–705. doi:10.1080/21645515.2017.1388480. Epub 2017 Dec 1. PubMed PMID: 29059004; PubMedCentral PMCID: PMC5861775.
   PubMed Web of Science ®Google Scholar
• Grohskopf LA, Sokolow LZ, Broder KR, Walter EB, Fry AM, Jernigan DB. Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization practices—United States, 2018–19 influenza season. MMWR Recomm Rep. 2018;67(No.RR–3):1–20. doi:10.15585/mmwr.rr6703a1. Hanon E, Van der Most R, Del Giudice G, Rappuoli R. Short-term and mid-term solutions for influenza vaccines. Lancet Infect Dis. 2018 Aug;18(8):832-833. doi:10.1016/S1473-3099(18)30404-3. PubMed PMID: 30064669.
   PubMed Web of Science ®Google Scholar
• Izurieta HS, Chillarige Y, Kelman J, Wei Y, Lu Y, Xu W, Lu M, Pratt D, Chu S, Wernecke M, et al. Relative effectiveness of cell-cultured and egg-based influenza vaccines among the U.S. elderly, 2017-18. J Infect Dis. 2018 Dec 18. doi:10.1093/infdis/jiy716.
   PubMed Web of Science ®Google Scholar
• Newall AT, Chaiyakunapruk N, Lambach P, Hutubessy RC WHO guide on the economic evaluation of influenza vaccination. Influenza Other Respir Viruses. 2018 Mar;12(2):211–19. doi:10.1111/irv.12510. Epub 2017 Dec 27.
   PubMed Web of Science ®Google Scholar
• Krimsky S. Do financial conflicts of interest bias research?: an inquiry into the “Funding Effect” hypothesis. Sci Technol Hum Values. 2013;38(4):566–87. doi:10.1177/0162243912456271.
   Web of Science ®Google Scholar
• Naci H, Dias S, Ades AE. Industry sponsorship bias in research findings: a network meta-analysis of LDL cholesterol reduction in randomised trials of statins. BMJ. 2014 Oct 3;349:g5741. doi:10.1136/bmj.g5741.
   PubMed Web of Science ®Google Scholar
• Coudeville L, Andre P, Bailleux F, Weber F, Plotkin S. A new approach to estimate vaccine efficacy based on immunogenicity data applied to influenza vaccines administered by the intradermal or intramuscular routes. Hum Vaccin. 2010;6:841–48.
   PubMed Web of Science ®Google Scholar
• Podda A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine. 2001;19(17–19):2673–80. doi:10.1016/S0264-410X(00)00499-0.
   PubMed Web of Science ®Google Scholar
• Banzhoff A, Nacci P, Podda A. A new MF59-adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: results from an immunogenicity meta–analysis. Gerontology. 2003;49(3):177–84. doi:10.1159/000069172.
   PubMed Web of Science ®Google Scholar
• Lee JKH, Lam GKL, Shin T, Kim J, Krishnan A, Greenberg DP, Chit A. Efficacy and effectiveness of high-dose versus standard-dose influenza vaccination for older adults: a systematic review and meta-analysis. Expert Rev Vaccines. 2018 May;17(5):435–43. doi:10.1080/14760584.2018.1471989.
   PubMed Web of Science ®Google Scholar
• Belshe RB, Coelingh K, Ambrose CS, Woo JC, Wu X. Efficacy of live attenuated influenza vaccine in children against influenza B viruses by lineage and antigenic similarity. Vaccine. 2010 Feb 25;28(9):2149–56. doi:10.1016/j.vaccine.2009.11.068.
   PubMed Web of Science ®Google Scholar
• Skowronski DM, Chambers C, De Serres G, Sabaiduc S, Winter AL, Dickinson JA, Gubbay JB, Drews SJ, Fonseca K, Charest H, et al. Vaccine effectiveness against lineage matched and mismatched influenza B viruses across 8 seasons in Canada, 2010-11 to 2017-18. Clin Infect Dis. 2018 Oct 11 . doi:10.1093/cid/ciy876.
   Google Scholar
• Beyer WEP, Palache AM, Boulfich M, Osterhaus ADME. Rationale for two influenza B lineages in seasonal vaccines: A meta-regression study on immunogenicity and controlled field trials. Vaccine. 2017 Jul 24;35(33):4167–76. doi:10.1016/j.vaccine.2017.06.038.
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO) Regional Office for Europe. Guidelines in health care practice. http://www.euro.who.int/__data/assets/pdf_file/0011/118379/E53492.pdf
   Google Scholar